We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 05, 2022

No Increase in Serum NfL Levels in Patients With Relapsing–Remitting MS Switching From Standard to Extended-Interval Dosing of Natalizumab

Multiple Sclerosis (Houndmills, Basingstoke, England)

 

Additional Info

Disclosure statements are available on the authors' profiles:

Multiple Sclerosis (Houndmills, Basingstoke, England)
No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
Mult. Scler. 2022 Jul 20;[EPub Ahead of Print], M Johnsson, HH Farman, K Blennow, H Zetterberg, C Malmeström, M Axelsson, J Lycke

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading